ProjectATTICUS – Apixaban for treatment of embolic stroke of undetermined source

Basic data

Acronym:
ATTICUS
Title:
Apixaban for treatment of embolic stroke of undetermined source
Duration:
10/1/2015 to 2/28/2021
Abstract / short description:
Study Design: ATTICUS is a multicentre (national, Germany), randomized, blinded, parallel group, active controlled, phase III clinical trial with adaptive study design.
Patient population: Max. total number of 600 patients with Embolic Stroke of Undetermined Source (ESUS) and at least one risk factor for cardiac embolism.
Aim of Study: Show superior efficacy of apixaban over aspirin (standard of care) in reduction of new ischemic lesions detected by MRI in patients with ESUS, and to show safety (similar risk of major and clinically non-major bleedings defined by ISTH criteria) compared to standard of care.
Keywords:
Apixaban
Embolie
Eliquis
Aspirin
cardiovascular disease
Herzkreislauferkrankungen
stroke
Schlaganfall

Involved staff

Managers

Department of Internal Medicine
Hospitals and clinical institutes, Faculty of Medicine
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Faculty of Medicine
University of Tübingen

Contact persons

Faculty of Medicine
University of Tübingen

Local organizational units

Department of Internal Medicine
Hospitals and clinical institutes
Faculty of Medicine
Department of Neurology with Focus on Neurovascular Diseases
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine

Funders

New York, United States of America
Help

will be deleted permanently. This cannot be undone.